{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:16:32Z","timestamp":1782285392787,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10147-024-02482-7","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T16:02:08Z","timestamp":1709395328000},"page":"612-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-8223","authenticated-orcid":false,"given":"Masaki","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagenori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIrokazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"2482_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"2482_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"2482_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cas.14762","volume":"112","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ito K, Kojima T et al (2021) Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 112:760\u2013773. https:\/\/doi.org\/10.1111\/cas.14762","journal-title":"Cancer Sci"},{"key":"2482_CR4","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1200\/JCO.19.01213","volume":"38","author":"J Vuky","year":"2020","unstructured":"Vuky J, Balar AV, Castellano D et al (2020) Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 38:2658\u20132666. https:\/\/doi.org\/10.1200\/JCO.19.01213","journal-title":"J Clin Oncol"},{"key":"2482_CR5","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1634\/theoncologist.2019-0039","volume":"24","author":"RB Parikh","year":"2019","unstructured":"Parikh RB, Galsky MD, Gyawali B et al (2019) Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist 24:e397\u2013e399. https:\/\/doi.org\/10.1634\/theoncologist.2019-0039","journal-title":"Oncologist"},{"key":"2482_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03291-5","author":"W Fukuokaya","year":"2022","unstructured":"Fukuokaya W, Yanagisawa T, Hashimoto M et al (2022) Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-022-03291-5","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2482_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.euf.2023.01.019","volume":"9","author":"T Kawada","year":"2023","unstructured":"Kawada T, Yanagisawa T, Mostafaei H et al (2023) Impact of performance status on oncologic outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitor: a systematic review and meta-analysis. Eur Urol Focus 9(2):264\u2013274. https:\/\/doi.org\/10.1016\/j.euf.2023.01.019","journal-title":"Eur Urol Focus"},{"key":"2482_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"Q Hude","year":"2011","unstructured":"Hude Q, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"2482_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000362421","volume":"93","author":"R Mayr","year":"2014","unstructured":"Mayr R, May M, Burger M et al (2014) The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder. Urol Int 93:303\u2013310. https:\/\/doi.org\/10.1159\/000362421","journal-title":"Urol Int"},{"key":"2482_CR10","doi-asserted-by":"publisher","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","volume":"40","author":"W Fukuokaya","year":"2022","unstructured":"Fukuokaya W, Kimura T, Komura K et al (2022) Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. Urol Oncol 40:346.e1-346.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.020","journal-title":"Urol Oncol"},{"key":"2482_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8Get","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8Get","journal-title":"J Chronic Dis"},{"issue":"9","key":"2482_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/bjs.9854","volume":"102","author":"L Backemar","year":"2015","unstructured":"Backemar L, Lagergren P, Johar A (2015) Impact of co-morbidity on mortality after oesophageal cancer surgery. Br J Surg 102(9):1097\u20131105. https:\/\/doi.org\/10.1002\/bjs.9854","journal-title":"Br J Surg"},{"issue":"7","key":"2482_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","volume":"137","author":"Y Kobayashi","year":"2011","unstructured":"Kobayashi Y, Miura K, Hojo A et al (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079\u20131084. https:\/\/doi.org\/10.1007\/s00432-010-0973-x","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2482_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2337\/dc15-1335","volume":"39","author":"AL Schneider","year":"2016","unstructured":"Schneider AL, Kalyani RR, Golden S et al (2016) Diabetes and prediabetes and risk of hospitalization: the atherosclerosis risk in communities (ARIC) study. Diabetes Care 39(5):772\u2013779. https:\/\/doi.org\/10.2337\/dc15-1335","journal-title":"Diabetes Care"},{"key":"2482_CR15","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"2482_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.euf.2021.08.00","volume":"8","author":"A Richters","year":"2022","unstructured":"Richters A, Boormans JL, van der Heijden MS et al (2022) Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study. Eur Urol Focus 8:995\u20131002. https:\/\/doi.org\/10.1016\/j.euf.2021.08.00","journal-title":"Eur Urol Focus"},{"key":"2482_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41","journal-title":"Biometrika"},{"key":"2482_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2017.2374","volume":"4","author":"T Seisen","year":"2018","unstructured":"Seisen T, Jamzadeh A, Leow JJ et al (2018) Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol 4:225\u2013229. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2374","journal-title":"JAMA Oncol"},{"key":"2482_CR19","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0-Japan Clinical Oncology Group (2017). Available from http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv4J_20170912_v20_1.pdf. Accessed Feb 2023"},{"key":"2482_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30:970\u2013976. https:\/\/doi.org\/10.1093\/annonc\/mdz127","journal-title":"Ann Oncol"},{"key":"2482_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/JU.0000000000000136","volume":"202","author":"J-M Lavoie","year":"2019","unstructured":"Lavoie J-M, Black PC, Eigl BJ (2019) Predictive biomarkers for checkpoint blockade in urothelial cancer: a systematic review. J Urol 202:49\u201356. https:\/\/doi.org\/10.1097\/JU.0000000000000136","journal-title":"J Urol"},{"issue":"1","key":"2482_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10147-021-02061-0","volume":"27","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa T, Mori K, Katayama S et al (2022) Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol 27(1):59\u201371. https:\/\/doi.org\/10.1007\/s10147-021-02061-0","journal-title":"Int J Clin Oncol"},{"key":"2482_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J et al (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91:8\u201335. https:\/\/doi.org\/10.1159\/000521288","journal-title":"Psychother Psychosom"},{"key":"2482_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","volume":"29","author":"L Lee","year":"2011","unstructured":"Lee L, Cheung WY, Atkinson E et al (2011) Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 29:106\u2013117. https:\/\/doi.org\/10.1200\/JCO.2010.31.3049","journal-title":"J Clin Oncol"},{"key":"2482_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252925","volume":"16","author":"M Salas","year":"2021","unstructured":"Salas M, Henderson M, Sundararajan M et al (2021) Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: a systematic review. PLoS ONE 16:e0252925. https:\/\/doi.org\/10.1371\/journal.pone.0252925","journal-title":"PLoS ONE"},{"key":"2482_CR26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/lary.29905","volume":"132","author":"K Pai","year":"2022","unstructured":"Pai K, Baaklini C, Cabrera CI et al (2022) The utility of comorbidity indices in assessing head and neck surgery outcomes: A systematic review. Laryngoscope 132:1388\u20131402. https:\/\/doi.org\/10.1002\/lary.29905","journal-title":"Laryngoscope"},{"key":"2482_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/0284186X.2021.2023213","volume":"61","author":"MT Mouritzen","year":"2022","unstructured":"Mouritzen MT, Junker KF, Carus A et al (2022) Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta Oncol 61:409\u2013416. https:\/\/doi.org\/10.1080\/0284186X.2021.2023213","journal-title":"Acta Oncol"},{"key":"2482_CR28","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.922576","volume":"26","author":"X Zeng","year":"2020","unstructured":"Zeng X, Zhu S, Xu C et al (2020) Effect of comorbidity on outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD1 immunotherapy. Med Sci Monit 26:e922576. https:\/\/doi.org\/10.12659\/MSM.922576","journal-title":"Med Sci Monit"},{"issue":"15_suppl","key":"2482_CR29","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2020.38.15_suppl.7039","volume":"38","author":"A Johns","year":"2020","unstructured":"Johns A, Wei L, Grogan M et al (2020) Association of medical comorbidities and cardiovascular disease with toxicity and survival in patients receiving checkpoint inhibitor immunotherapy. J Clin Oncol 38(15_suppl):7039\u20137039. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7039","journal-title":"J Clin Oncol"},{"key":"2482_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.20517\/cdr.2020.11","volume":"3","author":"Y Fujiwara","year":"2020","unstructured":"Fujiwara Y, Mittra A, Naqash AR et al (2020) A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. Cancer Drug Resist 3:252\u2013275. https:\/\/doi.org\/10.20517\/cdr.2020.11","journal-title":"Cancer Drug Resist"},{"key":"2482_CR31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Hyungseok S et al (2019) Nr4a transcription factors limit CAR T cell function in solid tumors. Nature 567:530\u2013534. https:\/\/doi.org\/10.1038\/s41586-019-0985-x","journal-title":"Nature"},{"key":"2482_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-71946-3","volume":"10","author":"I Nojima","year":"2020","unstructured":"Nojima I, Eikawa S, Tomonobu N et al (2020) Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis. Sci Rep 10:1\u20132. https:\/\/doi.org\/10.1038\/s41598-020-71946-3","journal-title":"Sci Rep"},{"key":"2482_CR33","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.3390\/ijerph17114135","volume":"17","author":"D Margin\u0103","year":"2020","unstructured":"Margin\u0103 D, Ungurianu A, Purdel C et al (2020) Chronic inflammation in the context of everyday life: dietary changes as mitigating factors. Int J Environ Res Public Health 17:4135. https:\/\/doi.org\/10.3390\/ijerph17114135","journal-title":"Int J Environ Res Public Health"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02482-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T03:42:58Z","timestamp":1714016578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02482-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2482"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02482-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"27 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An Institutional Reviewer Board approved the research protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and registration no. of the study\/trial"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}